TriangleHEALTH PROFESSIONAL · SOURCE READING
ATA pediatric low risk
Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Initial postoperative staging includes a TSH-suppressed thyroglobulin. A diagnostic iodine I 123 (123I) scan is not required.
TSH suppression should be targeted to serum levels of 0.5 to 1.0 mIU/L.
In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then annually for 5 years, as well as TSH-suppressed thyroglobulin levels every 3 to 6 months for 2 years and then annually.
In children with positive thyroglobulin antibodies (common in patients with Hashimoto thyroiditis), trending thyroglobulin is less reliable, and a diagnostic 123I scan may be required.
Preserved source evidence · Not medical advice